TSX Venture: QPT
EDMONTON, July 19, 2017 /CNW/ - Quest PharmaTech Inc.
(TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company
developing and commercializing products to improve the quality of
life, today announced the appointment of Mr. Mark Lievonen, to the Company's Board of
Directors. Mr. Lievonen has over 30 years' experience in the
pharmaceutical industry, more recently as the President of Sanofi
Pasteur Limited, the Canadian vaccine division of Sanofi, a global
pharmaceutical company.
Mr. Lievonen has received many awards and honours, including his
appointment to the Order of Canada
in 2015. He was named a Chevalier de l'Ordre National de
Mérite by the government of France
in 2007, and was inducted into the Canadian Healthcare Marketing
Hall of Fame in 2013.
Mr. Lievonen holds a BBA in accounting and an MBA in finance and
marketing from the Schulich School of Business, York University. He is a Chartered Professional
Accountant and received his designation while working with
PricewaterhouseCoopers prior to joining Sanofi Pasteur. He
was elected as a Fellow of the Institute of Chartered Accountants
of Ontario in 2007.
"We are very pleased that Mr. Lievonen has agreed to join our
Board," said Dr. Madi R.
Madiyalakan, Chief Executive Officer for Quest. "Mr.
Lievonen brings a wealth of biopharmaceutical experience to the
Board."
The Company also announces the resignation of Mr. Ian McConnan, FCA, from the Company's Board of
Directors. Mr. McConnan has been a Company Board of Director
for the past 14 years and served as Audit Committee Chair.
"I would like to thank Mr. McConnan for his support and tireless
work on the Board," said Dr. Madi R.
Madiyalakan. "Mr. McConnan has provided valuable
assistance to the Company over the many years he served as a Board
member".
The Company will grant 150,000 Company stock options to Mr.
Lievonen, exercisable at $0.15 per
common share, as part of his honorarium.
About Quest PharmaTech Inc.
Quest PharmaTech is a
publicly traded; Canadian based pharmaceutical company developing
products to improve the quality of life. The Company through its
subsidiary, OncoQuest and its Chinese joint venture, OncoVent, is
developing antibody based immunotherapeutic products for cancer. In
addition, the Company owns the Photodynamic Therapy technology for
oncology and dermatology applications, licensed to BioCeltran Co.,
Ltd., a Korea based company (Bioceltran). Quest has an
ownership interest in Bioceltran, which is focused on SP
Technology™ for transdermal delivery of drugs and photosensitizers
for pharmaceutical and cosmetic purposes. Quest through another
subsidiary, Madenco Biosciences, also markets consumer health
products worldwide, including Bellus Skin™ serum, a premium
anti-wrinkle skin care product licensed from Korea. Quest is
also developing an antibody licensed from University of Nebraska, Mab AR 9.6 against
truncated O-glycan on MUC16, for targeted cancer therapy
applications.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Quest PharmaTech Inc.